Pier Luigi Zinzani

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

2016 | 1. lékařská fakulta

Publikace